Researchers unveil an unanticipated impact of a widely-used bowel movement alleviator
In a groundbreaking study published in the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, researchers have discovered that prucalopride, a drug primarily used to treat constipation, may have potential therapeutic benefits for symptoms of mental impairment.
The study recruited 50 healthy volunteers, half of whom took prucalopride for six days, and the other half received a placebo. Participants were unaware of their group allocation, and the prucalopride and placebo capsules were identical. During the study, participants were asked to relax but keep their eyes open while data collection in the resting state was conducted. After six days, the participants underwent functional magnetic resonance imaging (fMRI) scans in a resting state.
The results showed that participants receiving prucalopride exhibited increased functional connectivity at rest between the central executive network (CEN) and a cluster consisting of the posterior (PCC) and anterior (ACC) cingulate cortices. They also demonstrated decreased functional connectivity in the default mode network (DMN) compared to those receiving placebo. Interestingly, connectivity was reduced between the left and right hippocampus, the inferior temporal lobe, and the inferior frontal gyrus in participants receiving prucalopride.
These findings suggest that prucalopride can positively affect cognitive functions, particularly in aspects related to learning and memory. This effect is thought to arise from prucalopride's action on serotonin 5-HT4 receptors, which are not only present in the gut but also widely expressed in the brain, including regions like the hippocampus that are crucial for cognitive processes.
The study highlights prucalopride’s potential to modulate neural systems involved in cognition beyond its gastrointestinal role, suggesting it could be repurposed or further developed as a therapeutic agent for cognitive impairments related to various neurological or psychiatric conditions. However, the precise mechanisms whereby prucalopride exerts these central effects require further investigation, including its impact on neurotransmitter systems like glutamate and cholinergic pathways implicated in cognitive function.
In summary, prucalopride shows promise as a cognitive enhancer with potential therapeutic applications for mental impairments, supporting the idea of gut-brain axis modulation by gut-targeted drugs influencing brain function. This aligns with a growing body of research on serotonergic modulation of cognition and neuroprotection. The researchers are confident that these study results will contribute to the list of treatments for depression and cognitive impairments.
Science has unveiled a possible link between the gut and brain function with the potencial therapeutic benefits of prucalopride, a drug primarily used for constipation, in enhancing cognitive functions and alleviating mental impairments. This drug, when administered for six days to healthy volunteers in a study, showed significant changes in functional connectivity of the brain, specifically in areas like the central executive network, cingulate cortices, default mode network, and hippocampus, which are key regions for cognitive processes. Thus, the health-and-wellness industry and mental-health therapies-and-treatments may consider exploring the repurposing or further development of prucalopride for neurological or psychiatric conditions.
